Dr. Matthias Magoola, the founder and Chief Executive Officer of Dei Group of Companies, has been awarded a Professional Doctorate (PD) in Management by the European International University of France.
The award was announced by the University based in Paris, France on February 19, 2024.
Dr. Magoola, a published advanced therapeutics researcher and innovator, has accomplished medical research projects that include new treatment for malaria using N-Isobutyll-3, 4-metheylenedioxy-trans-cinnamide compositions, patented in the USA.
His research projects have also led to the introduction of new vaccines and treatment for HiV/HPV, malaria, cancer and neuro-degenerative disorders, including Alzheimer, Parkinson’s and diabetes, also patented in the USA.
One of these inventions is the “mNRA-Based Vaccine Composition for Inducing Immune Response Against HIV and HPV” patented under certificate number 63921929 in the USA.
Dr. Magoola, who has more than 10 innovative patents focusing on new advanced therapies will next month lead a team of fellow scientists for a meeting at the FDA of the USA to discuss their first product submission on a new innovation to treat cancers and severe anemia, using mNRA technology.
Dr. Magoola has co-authored several publications that, after peer review by several scientists, have been accepted and published by the most prestigious journals in the world, the latest being the study titled, “Synergistic Approaches in Neurodegenerative Therapeutics: Multi-Target Drug Innovative Interventions for Alzheimer’s Disease,” which has been published in Pharmaceuticals, a peer-reviewed, open-access Journal of medicinal chemistry and related drug sciences.
The key others include “Advances in Escherichia coli-Based Therapeutic Protein Expression: Mammalian Conversion, Continuous Manufacturing, and Cell-Free Production” – published in the Biologics journal.
Dr. Magoola has also co-authored “mRNA and Synthesis-Based Therapeutic Proteins: A Non-Recombinant Affordable Option” – published in the biologics journal.
Dr. Magoola described his doctorate and the publications as key milestones in the fight against several incurable diseases including neurodegenerative disorders, HiV/Aids, HPV, and cancers.
“We have found the most innovative new ways to treat nneurodegenerative disorders for the first time,” he said.
These publications and innovative cutting-edge discoveries to treat different rare diseases is giving a positive image to Ugandan researchers and authors around the world of scientists and researchers globally.
On February 24, 2024, Mr Magoola was also awarded the 10th International Excellence and Global Leadership Award by Fame Times International Excellence Awards in Bangkok, Thailand. He was recognised for his visionary success and achievements for his innovative discoveries in advanced therapies.
About Dr. Magoola
Magoola a trained biochemist has led the Dei Group over the years to birth a portfolio of sub-companies across diverse sectors, including the current development of the flagship biological drugs and vaccines manufacturing facility in Matugga, Wakiso District, in Uganda, being spearheaded by Dei Biopharma Ltd.
Its flagship product, The Dei Anti-Malarial drug derived from natural sources, had its active ingredient isolation process performed in the United States of America in the latest cutting-edge laboratories that led to the isolation of “N-Isobutyll-3, 4-metheylenedioxy-trans-cinnamide compositions” patented in the USA. It was confirmed to be the most effective anti-malarial drug ever discovered; with a US patent, this will be the first new drug for malaria treatment among the patents owned by Dr. Magoola.
Dr. Magoola thanks President Yoweri Museveni, for his unwavering support to Ugandan scientists and in particular to the Dei Biopharma drugs and vaccines manufacturing project, the first biotech facility in Africa.
“Without his dedicated support, we wouldn’t be achieving these milestones and it is fair that we must thank and credit him for these achievements. These achievements are for Uganda and specifically for our dear President for he has always stood up for the scientists in this country,” he said.
Upon completion, the project, whose total cost is USD 1.1 billion will produce a wide range of medicines and vaccines including anti-cancer drugs and therapeutic proteins.